(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 June 2011 (16.06.2011)

PCT

(10) International Publication Number
WO 2011/072263 A1

(51) International Patent Classification:
C07K 16/40 (2006.01) *A61P 3/06* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2010/059959

(22) International Filing Date:
10 December 2010 (10.12.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/285,942 11 December 2009 (11.12.2009) US

(71) Applicants *(for all designated States except US)*: **IRM LLC** [US/—]; 131 Front Street, Hamilton, HM LX (BM). **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **RUE, Sarah** [US/US]; 4028 Carmel Springs Way, San Diego, California 92130 (US). **COHEN, Steven, B.** [US/US]; 4104 Via Candidiz #89, San Diego, California 92130 (US). **LI, Jun** [CN/US]; 11618 Trailbrush Point, San Diego, California 92126 (US). **YOWE, David** [US/US]; 34 Fairview Avenue, Belmont, Massachusetts 02478 (US).

(74) Agents: **SMITH, Timothy, L.** et al.; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: PCSK9 ANTAGONISTS

(57) Abstract: The present disclosure provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a ("PCSK9") and methods of using such antibodies.

WO 2011/072263 A1